AGEN · Insider Trading
Agenus Inc.
Every open-market purchase and sale reported by AGEN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Timothy Wright | Director | A | +1,178 deriv. | — |
| 2026-10-02 | Thomas L Harrison | Director | A | +4,443 | +$30.63K |
| 2026-09-16 | Marco Tullio Marcucci | Director | A | +7,500 deriv. | — |
| 2026-08-12 | Garo H Armen | See Remarks | A | +1,971,500 deriv. | — |
| 2026-08-11 | Brian Corvese | Director | A | +100,000 deriv. | — |
| 2026-08-11 | Thomas L Harrison | Director | A | +50,000 deriv. | — |
| 2026-08-07 | Timothy Wright | Director | A | +50,000 deriv. | — |
| 2026-08-07 | Steven J O'Day | Chief Medical Officer | A | +100,000 deriv. | — |
| 2026-08-07 | Jennifer Buell | See Remarks | A | +200,000 deriv. | — |
| 2026-08-07 | Susan B Hirsch | Director | A | +50,000 deriv. | — |
| 2026-08-07 | Jennifer Buell | See Remarks | A | +200,000 deriv. | — |
| 2026-08-07 | Timothy Wright | Director | A | +50,000 deriv. | — |
| 2026-08-07 | Steven J O'Day | Chief Medical Officer | A | +100,000 deriv. | — |
| 2026-08-07 | Susan B Hirsch | Director | A | +50,000 deriv. | — |
| 2026-07-14 | Garo H Armen | See Remarks | A | +4,852 | +$16.25K |
| 2026-07-07 | Thomas L Harrison | Director | A | +8,547 | +$30.62K |
| 2026-07-07 | Timothy Wright | Director | A | +2,267 deriv. | — |
| 2026-06-16 | Garo H Armen | See Remarks | A | +4,925 | +$16.25K |
| 2026-06-02 | Garo H Armen | See Remarks | A | +4,644 | +$16.25K |
| 2026-05-19 | Garo H Armen | See Remarks | A | +4,540 | +$16.25K |
| 2026-05-05 | Garo H Armen | See Remarks | A | +4,233 | +$16.25K |
| 2026-04-28 | Steven J O'Day | Chief Medical Officer | A | +165,333 deriv. | — |
| 2026-04-28 | Thomas L Harrison | Director | A | +122,500 deriv. | — |
| 2026-04-28 | Jennifer Buell | See Remarks | A | +305,000 deriv. | — |
| 2026-04-28 | Garo H Armen | See Remarks | A | +1,165,300 deriv. | — |
| 2026-04-28 | Susan B Hirsch | Director | A | +105,000 deriv. | — |
| 2026-04-28 | Timothy Wright | Director | A | +105,000 deriv. | — |
| 2026-04-28 | Austin Charette | Principal Accounting Officer | A | +22,619 deriv. | — |
| 2026-04-28 | Brian Corvese | Director | A | +210,000 deriv. | — |
| 2026-04-21 | Garo H Armen | See Remarks | A | +3,403 | +$16.30K |
| 2026-04-13 | Thomas L Harrison | Director | A | +9,228 | +$30.63K |
| 2026-04-06 | Garo H Armen | See Remarks | A | +4,629 | +$15.41K |
| 2026-04-02 | Timothy Wright | Director | A | +2,448 deriv. | — |
| 2026-03-24 | Garo H Armen | See Remarks | A | +3,983 | +$14.78K |
| 2026-03-09 | Garo H Armen | See Remarks | A | +4,994 | +$14.78K |
| 2026-02-24 | Garo H Armen | See Remarks | A | +4,829 | +$14.78K |
| 2026-02-09 | Garo H Armen | See Remarks | A | +5,027 | +$14.78K |
| 2026-01-26 | Garo H Armen | See Remarks | A | +4,562 | +$14.78K |
| 2026-01-12 | Garo H Armen | See Remarks | A | +3,780 | +$14.78K |
| 2026-01-05 | Thomas L Harrison | Director | A | +7,691 | +$30.63K |
| 2026-01-05 | Timothy Wright | Director | A | +2,040 deriv. | — |
| 2025-12-29 | Garo H Armen | See Remarks | A | +4,942 | +$16.36K |
| 2025-12-15 | Garo H Armen | See Remarks | A | +4,316 | +$16.36K |
| 2025-12-01 | Garo H Armen | See Remarks | A | +3,587 | +$16.36K |
| 2025-11-17 | Garo H Armen | See Remarks | A | +3,769 | +$16.36K |
| 2025-11-05 | Garo H Armen | See Remarks | A | +4,120 | +$16.36K |
| 2025-10-21 | Garo H Armen | See Remarks | A | +4,216 | +$16.36K |
| 2025-10-06 | Garo H Armen | See Remarks | A | +3,951 | +$16.36K |
| 2025-10-03 | Timothy Wright | Director | A | +1,704 deriv. | — |
| 2025-10-03 | Thomas L Harrison | Director | A | +5,780 | +$28.96K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Garo H Armen | See Remarks | 402,406 | $2.60M |
| Steven J O'Day | Chief Medical Officer | 57,116 | $369.20K |
| Thomas L Harrison | Director | 51,988 | $336.05K |
| Christine M Klaskin | PFO & PAO | 23,480 | $151.77K |
| Jennifer Buell | See Remarks | 19,738 | $127.59K |
| Susan B Hirsch | Director | 5,436 | $35.14K |
| Brian Corvese | Director | 4,604 | $29.76K |
| Timothy Wright | Director | 2,520 | $16.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AGEN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.